Paul DiCorleto, PhD


Paul DiCorleto, Ph.D.

Appointed: 1982

Paul DiCorleto, PhD
Department: Lerner Research Institute
Institute Chair
Location: Cleveland Clinic Main Campus
Mail Code NB21
9500 Euclid Avenue
Cleveland, OH 44195
Paul DiCorleto, PhD
Department: Cardiovascular Medicine
Location: Cleveland Clinic Main Campus
Mail Code NB21
9500 Euclid Avenue
Cleveland, OH 44195
Paul DiCorleto, PhD
Department: Cellular and Molecular Medicine
Location: Cleveland Clinic Main Campus
Mail Code NB21
9500 Euclid Avenue
Cleveland, OH 44195
Adults Only

Biographical Sketch

Vascular Endothelial Cell Gene Expression Linked to Atherosclerosis

Current program:
  • Endothelial Cell Expression of Leukocyte Adhesion Molecules
  • Homeobox Gene Expression by the Endothelium
  • Regulation of PDGF Production by the Endothelium
  • Eugene Podrez, MD, PhD, Staff Scientist
  • Smarajit Bandyopadhyay, PhD, Research Associate
  • Unni Chandrasekharan, PhD, Research Associate
  • Zahid Ashraf, PhD, Postdoctoral Fellow
  • Lori Mavrakis, BA, Technologist Graduate Student
  • Corttrell Kinney, BS, Student
  • Kristin Ilagan, BA, Research Student
  • Sara Bundy, BS, Technician
  • Chandani Lewis, MD, Research Fellow
  • Marc Penn, MD, PhD
  • Maria Siemionow, MD, PhD
  • Vikram Kashyap, MD
Brief Description:

The central objective of our research is to understand the role of endothelial cell (EC) gene expression in blood vessel wall homeostasis and the genesis of vascular diseases. Our working hypothesis is that aberrant expression of embryonic or "pathological" genes in adult ECs leads to atherosclerotic plaque development and other inflammatory diseases.

We are pursuing the thrombin- and cytokine-activated intracellular signaling pathways and transcription factors responsible for induction of leukocyte adhesion to ECs in vivo and in vitro. We are currently focused on the relative importance of the two tumor necrosis factor-Ü receptors in the induction of leukocyte adhesion. Furthermore, we are testing the hypothesis that homeobox (HOX) genes, a family of master-control transcription factors, are involved in the process of cytokine-induced activation of ECs. We have discovered that the HOXA9 gene is required for cytokine-induced expression of the EC-leukocyte adhesion molecule E-selectin. We are identifying other EC genes that are regulated by HOXA9, and we are pursuing binding partners of HOXA9 in the EC nucleus.

Finally, we are characterizing regulatory pathways involved in the expression of inflammatory genes by ECs in response to the protease thrombin and the angiogenic agent vascular endothelial growth factor (VEGF). We are defining the mechanism of induction of the dual-specificity nuclear phosphatase MAP kinase phosphatase-1 (MKP-1) by thrombin and VEGF in ECs and determining MKP-1's role as an immediate early gene product in the induction of various downstream genes.

Professional Highlights

  • Institute Chairman, Lerner Research Institute, Cleveland Clinic, Sherwin-Page Endowed Chair in Biomedical Research, 2002-Present
  • Chairman, Department of Molecular Medicine, Case School of Medicine, Case Western Reserve University, 2003-Present
  • Chairman, Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Jan Bleeksma Endowed Chair in Vascular Biology, 1989-2002
  • Associate Chief of Staff, Cleveland Clinic, 1997-2001
  • Vice Chairman, Lerner Research Institute, Cleveland Clinic, 1996-1999

Education & Fellowships

Doctorate - Cornell University
Ithaca, NY USA
Undergraduate - Rensselaer Polytechnic Institute
Troy, NY USA

Specialty Interests

endothelium, cell growth control, vascular cell interactions

Awards & Honors

  • Fellow, American Association for the Achievement of Science, 2007
  • Distinguished Achievement Award in Basic Science, Cleveland Clinic, 2004
  • President, North American Vascular Biology Organization, 2002-2003
  • Special Recognition Award of the AVTB Council, American Heart Association, 2001
  • Member, Advisory Panel on Research, Association of American Medical Colleges, 1999-Present
  • Member, Heart, Lung and Blood Program Project Review Committee, NHLBI, 1995-1999
  • Member, Board of Governors, Cleveland Clinic, 1990-1995
  • Visiting Scholar of the British Heart Fund, 1991
  • NIH Cellular Biology and Physiology Study Section -- member, 1987-1991; chairman, 1990-1991
  • Founding Co-Chair, Gordon Research Conference on Vascular Cell Biology, 1988
  • NIH Research Center Career Development Award, 1985-1990
  • DuPont Graduate Teaching Award, 1976
  • Merck Chemistry Award and the American Institute of Chemists Award, 1973
  • Rensselaer Medal Scholar, 1969-1973


American Heart Association

  • Fellow of the Council on Arteriosclerosis Executive Committee, 1992-1994
  • Fellow of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, Program Committee, 1997-2001
  • Spring Conference Chair, 2000-2001
  • Executive Committee, 1998-2003
  • Research Steering Committee, 2005-2008

American Society for Cell Biology

American Society of Investigative Pathology

  • Program Committee, 1992-1997
  • Nominating Committee, 1998-2000

North American Vascular Biology Organization

  • Program Committee Chair, Council Member, 1995-2001
  • President-Elect, 2001-2002
  • President, 2002-2003
  • Scientific Advisory Board, October 2007 to October 2012

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/2/2014, Dr. DiCorleto has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Fiduciary Role. Dr. DiCorleto serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:

  • Cleveland BioLabs, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
Cleveland Clinic Mobile Site